RU2007148195A - Пероральные дозированные формы о-десметилвенлафаксин сукцината повышенной биодоступности с отсроченным высвобождением - Google Patents
Пероральные дозированные формы о-десметилвенлафаксин сукцината повышенной биодоступности с отсроченным высвобождением Download PDFInfo
- Publication number
- RU2007148195A RU2007148195A RU2007148195/15A RU2007148195A RU2007148195A RU 2007148195 A RU2007148195 A RU 2007148195A RU 2007148195/15 A RU2007148195/15 A RU 2007148195/15A RU 2007148195 A RU2007148195 A RU 2007148195A RU 2007148195 A RU2007148195 A RU 2007148195A
- Authority
- RU
- Russia
- Prior art keywords
- composition containing
- increased bioavailability
- bioavailability
- combustion engine
- internal combustion
- Prior art date
Links
- 206010012186 Delayed delivery Diseases 0.000 title 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract 35
- 239000011248 coating agent Substances 0.000 claims abstract 14
- 238000000576 coating method Methods 0.000 claims abstract 14
- 239000002552 dosage form Substances 0.000 claims abstract 14
- 238000002485 combustion reaction Methods 0.000 claims abstract 13
- 238000013270 controlled release Methods 0.000 claims abstract 13
- ORUUBRMVQCKYHB-UHFFFAOYSA-N butanedioic acid;4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol Chemical compound OC(=O)CCC(O)=O.C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 ORUUBRMVQCKYHB-UHFFFAOYSA-N 0.000 claims abstract 9
- 239000004480 active ingredient Substances 0.000 claims abstract 8
- 230000003111 delayed effect Effects 0.000 claims abstract 6
- 239000001856 Ethyl cellulose Substances 0.000 claims abstract 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims abstract 4
- 235000019325 ethyl cellulose Nutrition 0.000 claims abstract 4
- 229920001249 ethyl cellulose Polymers 0.000 claims abstract 4
- 239000006185 dispersion Substances 0.000 claims abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 2
- 238000013268 sustained release Methods 0.000 claims abstract 2
- 239000012730 sustained-release form Substances 0.000 claims abstract 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 6
- 239000002702 enteric coating Substances 0.000 claims 5
- 238000009505 enteric coating Methods 0.000 claims 5
- 239000000454 talc Substances 0.000 claims 4
- 229910052623 talc Inorganic materials 0.000 claims 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 3
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 239000001069 triethyl citrate Substances 0.000 claims 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims 2
- 235000013769 triethyl citrate Nutrition 0.000 claims 2
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims 1
- 238000009512 pharmaceutical packaging Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000011253 protective coating Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69962305P | 2005-07-15 | 2005-07-15 | |
| US60/699,623 | 2005-07-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007148195A true RU2007148195A (ru) | 2009-08-20 |
Family
ID=37669348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007148195/15A RU2007148195A (ru) | 2005-07-15 | 2006-07-13 | Пероральные дозированные формы о-десметилвенлафаксин сукцината повышенной биодоступности с отсроченным высвобождением |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20070014859A1 (enExample) |
| EP (1) | EP1904040A2 (enExample) |
| JP (1) | JP2009501233A (enExample) |
| KR (1) | KR20080025405A (enExample) |
| CN (1) | CN101247791A (enExample) |
| AR (1) | AR054833A1 (enExample) |
| AU (1) | AU2006270315A1 (enExample) |
| BR (1) | BRPI0613484A2 (enExample) |
| CA (1) | CA2612960A1 (enExample) |
| CR (1) | CR9626A (enExample) |
| EC (1) | ECSP088106A (enExample) |
| GT (1) | GT200600307A (enExample) |
| IL (1) | IL188313A0 (enExample) |
| MX (1) | MX2008000666A (enExample) |
| NO (1) | NO20080088L (enExample) |
| PE (1) | PE20070192A1 (enExample) |
| RU (1) | RU2007148195A (enExample) |
| SV (1) | SV2008002612A (enExample) |
| TW (1) | TW200740427A (enExample) |
| WO (1) | WO2007011619A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ556673A (en) | 2005-02-03 | 2010-03-26 | Gen Hospital Corp | Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor |
| ES2335919T3 (es) * | 2005-03-31 | 2010-04-06 | Wyeth | Producto de combinacion de o-desmetilvenlafaxina y bazedosifeno, y sus usos. |
| US20080175873A1 (en) * | 2005-06-02 | 2008-07-24 | Biovail Laboratories International S.R.L. | Modified release composition of at least one form of venlafaxine |
| EP3488866A1 (en) | 2005-11-04 | 2019-05-29 | Wyeth LLC | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
| WO2007067501A1 (en) * | 2005-12-05 | 2007-06-14 | Wyeth | Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols |
| TW200806282A (en) * | 2006-05-05 | 2008-02-01 | Wyeth Corp | Solid dosage formulations |
| US20100210719A1 (en) * | 2007-07-12 | 2010-08-19 | Dr. Reddy's Laboratories Ltd. | O-desmethylvenlafaxine |
| US20100330172A1 (en) * | 2007-10-16 | 2010-12-30 | Alphapharm Pty Ltd | Controlled-release pharmaceutical formulation |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| US20110027324A1 (en) * | 2007-12-10 | 2011-02-03 | Wyeth Llc | O-desmethyl-venlafaxine for treating major depressive disorder |
| ES2531322T3 (es) | 2008-06-17 | 2015-03-13 | Wyeth Llc | Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina |
| EP3175853B1 (en) | 2008-08-04 | 2023-11-01 | Wyeth LLC | Antineoplastic combinations of neratinib and capecitabine |
| CN101716168B (zh) * | 2008-10-09 | 2014-09-17 | 北京德众万全医药科技有限公司 | 一种含有去甲文拉法新的盐的药物组合物及其制备方法 |
| EP2191822A1 (en) * | 2008-11-26 | 2010-06-02 | LEK Pharmaceuticals d.d. | Controlled release pharmaceutical compositions comprising O-desmethyl-venlafaxine |
| PT3000467T (pt) | 2009-04-06 | 2023-03-30 | Wyeth Llc | Regime de tratamento utilizando neratinib para o cancro de mama |
| EP2498751B1 (en) * | 2009-11-09 | 2019-04-03 | Wyeth LLC | Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea |
| EP2552419A2 (en) * | 2010-03-31 | 2013-02-06 | Wockhardt Limited | Modified release dosage form comprising desvenlafaxine or salts thereof |
| CN102085197B (zh) * | 2010-12-14 | 2013-08-14 | 北京万生药业有限责任公司 | 一种文拉法辛缓释制剂及其制备方法 |
| WO2012140577A1 (en) | 2011-04-12 | 2012-10-18 | Lupin Limited | Modified release pharmaceutical compositions of desvenlafaxine |
| CN111008356B (zh) * | 2019-11-13 | 2023-06-16 | 成都理工大学 | 一种基于WTSVD算法扣除背景的γ能谱集分析方法 |
| CN114288273B (zh) * | 2022-02-11 | 2022-10-18 | 桂林华信制药有限公司 | 一种盐酸文拉法辛缓释胶囊及其生产工艺 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274171B1 (en) * | 1996-03-25 | 2001-08-14 | American Home Products Corporation | Extended release formulation of venlafaxine hydrochloride |
| AU5738700A (en) * | 1999-06-15 | 2001-01-02 | American Home Products Corporation | Enantiomers of o-desmethyl venlafaxine |
| AR021347A1 (es) * | 1999-10-20 | 2002-07-17 | Cipla Ltd | Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma |
| US20030191347A1 (en) * | 2002-03-28 | 2003-10-09 | Rolf Keltjens | Venlafaxine base |
| US6703044B1 (en) * | 2002-10-25 | 2004-03-09 | Dexcel Pharma Tech, Ltd | Venlafaxine formulations |
| ES2277030T3 (es) * | 2003-05-02 | 2007-07-01 | Dexcel Ltd. | Formulacion en comprimidos de venlafaxina de liberacion prolongada. |
| WO2005077340A1 (en) * | 2004-02-06 | 2005-08-25 | Wyeth | Multiparticulate o-desmethylvenlafaxine salts and uses thereof |
| US8394409B2 (en) * | 2004-07-01 | 2013-03-12 | Intellipharmaceutics Corp. | Controlled extended drug release technology |
-
2006
- 2006-07-13 TW TW095125660A patent/TW200740427A/zh unknown
- 2006-07-13 KR KR1020087001067A patent/KR20080025405A/ko not_active Withdrawn
- 2006-07-13 GT GT200600307A patent/GT200600307A/es unknown
- 2006-07-13 SV SV2006002612A patent/SV2008002612A/es unknown
- 2006-07-13 PE PE2006000833A patent/PE20070192A1/es not_active Application Discontinuation
- 2006-07-13 BR BRPI0613484A patent/BRPI0613484A2/pt not_active IP Right Cessation
- 2006-07-13 MX MX2008000666A patent/MX2008000666A/es not_active Application Discontinuation
- 2006-07-13 WO PCT/US2006/027106 patent/WO2007011619A2/en not_active Ceased
- 2006-07-13 AR ARP060103012A patent/AR054833A1/es unknown
- 2006-07-13 US US11/486,324 patent/US20070014859A1/en not_active Abandoned
- 2006-07-13 AU AU2006270315A patent/AU2006270315A1/en not_active Abandoned
- 2006-07-13 CA CA002612960A patent/CA2612960A1/en not_active Abandoned
- 2006-07-13 CN CNA2006800258002A patent/CN101247791A/zh active Pending
- 2006-07-13 EP EP06787061A patent/EP1904040A2/en not_active Withdrawn
- 2006-07-13 JP JP2008521581A patent/JP2009501233A/ja not_active Withdrawn
- 2006-07-13 RU RU2007148195/15A patent/RU2007148195A/ru unknown
-
2007
- 2007-12-20 CR CR9626A patent/CR9626A/es not_active Application Discontinuation
- 2007-12-20 IL IL188313A patent/IL188313A0/en unknown
-
2008
- 2008-01-07 NO NO20080088A patent/NO20080088L/no not_active Application Discontinuation
- 2008-01-14 EC EC2008008106A patent/ECSP088106A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007011619A2 (en) | 2007-01-25 |
| CR9626A (es) | 2008-04-10 |
| AR054833A1 (es) | 2007-07-18 |
| CA2612960A1 (en) | 2007-01-25 |
| GT200600307A (es) | 2008-04-24 |
| IL188313A0 (en) | 2008-04-13 |
| SV2008002612A (es) | 2008-08-29 |
| WO2007011619A3 (en) | 2007-06-21 |
| US20070014859A1 (en) | 2007-01-18 |
| BRPI0613484A2 (pt) | 2016-11-16 |
| TW200740427A (en) | 2007-11-01 |
| JP2009501233A (ja) | 2009-01-15 |
| EP1904040A2 (en) | 2008-04-02 |
| AU2006270315A1 (en) | 2007-01-25 |
| PE20070192A1 (es) | 2007-03-16 |
| KR20080025405A (ko) | 2008-03-20 |
| NO20080088L (no) | 2008-04-02 |
| ECSP088106A (es) | 2008-02-20 |
| CN101247791A (zh) | 2008-08-20 |
| MX2008000666A (es) | 2008-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230346748A1 (en) | Pharmaceutical combination, composition and compound preparation containing glucokinase activator and k-atp channel blocker, preparation method therefor and use thereof | |
| JP4365107B2 (ja) | 医薬組成物 | |
| US20020197313A1 (en) | Unit dosage forms for the treatment of herpes simplex | |
| US20140275237A1 (en) | Beraprost isomer as an agent for the treatment of viral infection | |
| CN1316901A (zh) | 富马酸衍生物在移植药物中的应用 | |
| US20100203126A1 (en) | Multilayered vitamin complex tablet containing ubidecarenone | |
| KR20080025405A (ko) | Ｏ-데스메틸벤라팍신 숙시네이트의 고도로 생체이용가능한경구 지연 방출형 투여 형태 | |
| RU2007120570A (ru) | Пероральная дозированная форма кабапептина длительного выделения | |
| CN113633649B (zh) | 瑞德西韦及其核苷的组合制剂在抗猪流行性腹泻病毒中的应用 | |
| CN1112929C (zh) | 含有咪唑拉汀的缓释药物制剂 | |
| WO2014096982A1 (en) | Stable pharmaceutical compositions of saxagliptin or salts thereof | |
| WO2021244481A1 (en) | Compositions and methods for treating a sars-cov-2 infection | |
| RU2007143087A (ru) | Композиция с модифицированным высвобождением минимум одной формы венлафаксина | |
| RU2013126056A (ru) | Композиция для лечения нарушений иннерваций (варианты) | |
| RU2008115582A (ru) | Фармацевтическая композиция для лечения болезни паркинсона | |
| EA019805B1 (ru) | Комбинированный анальгетик на основе парацетамола | |
| CN105919991A (zh) | 泽兰素在制备治疗抑郁症药物中的应用 | |
| CN118161610A (zh) | Mapk通路抑制剂在抗病毒感染中的应用 | |
| RU2453308C1 (ru) | Драже с оксиметилурацилом и мебеверина гидрохлоридом для лечения функциональных заболеваний желудочно-кишечного тракта | |
| KR20010052895A (ko) | 치료 방법 | |
| KR101328383B1 (ko) | 유럽종 포도의 씨 추출물을 함유하는 경구용 정제 | |
| JPWO2001013911A1 (ja) | 高血圧性細動脈障害抑制剤 | |
| RU2009114885A (ru) | Фармацевтическая композиция в виде твердой пероральной лекарственной формы для лечения заболеваний желудочно-кишечного тракта | |
| KR20080075113A (ko) | 에스시탈로프람 및 부프로피온을 함유하는 안정한 약학적제형 | |
| US20230028539A1 (en) | Pharmaceutical composition, complementary kit and application thereof |